LumiraDx Ltd (LumiraDx) is a diagnostic company that develops, manufactures and markets point of care (PoC) systems to improve health outcomes of patients. Its PoC tests address unmet diagnostic needs of infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

LumiraDx's R&D efforts focus on improving and expanding its core technologies and tests. - In FY2022, the company’s R&D expense stood at US$141.6 million, which as a percentage of revenue stood at 55.6%, and grew 8.8% YoY. - As of December 31, 2022, LumiraDx has approximately 18 US patents, 100 foreign patents, 13 pending US non provisional patent applications, two pending The Patent Cooperation Treaty (PCT) patent applications, 50 foreign pending applications and four pending provisional patent applications in the US. Its intellectual property portfolio covers platform technologies, clinical assays, and Amira System. - It also has R&D collaborations with diagnostic companies to develop tests based on its LumiraDx platform. The company has 413 employees working on its R&D activities.